Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up.
Barni S, Piazza E, Frontini L, Visini M, Ardizzoia A, Grassi MM, Nosenzo MA, Mandalà M, Biasioli R, Freddi E, Lucani L, Recalcati A, Pravettoni A, Sala R, Rezzani C, Villa S, Trabucchi E; Neo-Adjuvant Breast Italian Group.
Barni S, et al. Among authors: grassi mm.
Oncology. 2004;67(1):40-7. doi: 10.1159/000080284.
Oncology. 2004.
PMID: 15459494
Clinical Trial.